

Noxopharm novel oligonucleotides data presented at Options XIII Conference

Highlights

- Project to improve next generation mRNA vaccines
- Results show clear promise
- Versatile technology attracting attention

Sydney, 1 Sep 2026: Clinical-stage biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce that promising data involving Noxopharm's technology has been presented at the International Society for Respiratory Viruses (ISRV), Options for the Control of Influenza XIII Conference.


The research, conducted by global biopharma company CSL, was designed to explore how Noxopharm's novel oligonucleotides from its [Sofra™](#) platform could be used to reduce the reactogenicity of self-amplifying mRNA (sa-mRNA) vaccines – a next-generation mRNA technology attracting worldwide interest and investment.

Despite offering greater dose efficiency and more durable immunity than conventional mRNA vaccines, the reactogenicity profile of both mRNA platforms is comparable.

To explore opportunities to improve reactogenicity profile, Noxopharm's anti-inflammatory oligos were co-delivered with sa-mRNAs, intended to decrease the immune activation that potentially contributes to the post-vaccination adverse reactions associated with investigational influenza sa-mRNA vaccines. The scientific poster presentation stated that the oligos "show clear promise" in reducing vaccine-related inflammation markers, confirming their potential in improving vaccine tolerability.

The graph below, taken from the presented poster, shows that the production of highly inflammatory interferon- α by the sa-mRNA vaccine (blue bars) was greatly reduced by Noxopharm's oligo, even at doses as low as one nanogram (orange bars).

Figure 1 – Significant reduction of interferon- α induced by sa-mRNA H1N1 LNP transfection in blood cells from three human donors



The presentation took place at the [Options for the Control of Influenza XIII Conference](#) in Washington DC, which is the largest global scientific meeting focused on influenza prevention, control and treatment.

Bringing together international experts in virology, clinical care, public health and vaccine research, speakers at this year's event included representatives from leading global institutions such as Johns Hopkins University, Princeton University, Massachusetts Institute of Technology, the World Health Organization, and the US Centers for Disease Control and Prevention, among many others.

Noxopharm CEO Dr Olivier Laczka said: "This presentation and these independent results further demonstrate the versatility of our technology. It is appealing to other companies because it can be used in conjunction with their own approaches to both new vaccine and new drug development.

"In light of Moderna and Merck's recent positive results from their cancer mRNA vaccine/Keytruda trial, and the potential for the mRNA vaccine market to grow rapidly, our approach could play a key role in the field.

"We will continue to pursue and develop external partnerships wherever they make strategic sense for us, and are confident that our Sofra platform will keep generating more interest in the future."

-ENDS-

About the Sofra technology platform

Developed from a [breakthrough discovery](#) in innate immunology, the Sofra technology platform represents a revolutionary approach to drug design by translating a new understanding of innate biology into targeted therapeutics that enable precision control of disease-relevant signalling.

Sofra is based on the use of synthetic nucleic acids, known as oligonucleotides, to mimic natural regulators of the body's defence system.

This novel approach enables selective and modular tuning of immune sensors, reducing or stimulating their associated biological responses to mitigate a broad range of diseases and enhance RNA-based therapies and emerging therapeutic technologies.

[Sofra](#) is focused on inflammatory and autoimmune diseases such as rheumatoid arthritis, lupus and diabetes, as well as immuno-oncology for cancer treatment. The global autoimmune disease therapeutics market was worth US\$163.2 billion in 2024 and is expected to reach US\$219.6 billion by 2035, while the worldwide immuno-oncology market was US\$43 billion in 2023 and is projected to hit US\$284 billion by 2033.

Further information and animations: [SOF-SKN](#) / [SOF-VAC](#)

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage biotechnology company developing novel, targeted therapies for inflammation, autoimmune diseases and cancer.

Noxopharm's proprietary Sofra™ platform is designed to regulate innate immune signalling with greater precision. Its lead clinical asset, SOF-SKN™, is a topical therapy initially being developed for cutaneous lupus erythematosus, with Phase I completed and further clinical development progressing.

Beyond SOF-SKN, the Sofra platform supports a broader pipeline of internal and externally collaborated programs across inflammatory and autoimmune diseases, RNA therapeutics and oncology.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

Shawn van Boheemen

T: +61 414 903 376

E: shawn.vanboheemen@noxopharm.com

Noxopharm CEO Dr Olivier Laczka has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.